Healius Limited (ASX:HLS)
Australia · Delayed Price · Currency is AUD | Market Cap | 272.31M -50.3% |
| Revenue (ttm) | 1.37B +6.0% |
| Net Income | -168.80M |
| EPS | -0.23 |
| Shares Out | 726.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.41 (110.13%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 2,435,823 |
| Open | 0.3950 |
| Previous Close | 0.4000 |
| Day's Range | 0.3700 - 0.4050 |
| 52-Week Range | 0.3000 - 1.0700 |
| Beta | 0.28 |
| Analysts | Sell |
| Price Target | 0.51 (+36.0%) |
| Earnings Date | Aug 19, 2026 |
About Healius
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ... [Read more]
Financial Performance
In fiscal year 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for HLS stock is "Sell." The 12-month stock price target is $0.51, which is an increase of 36.00% from the latest price.
News
Healius Earnings release: Trading update
Healius released its earnings on May 12, 2026, summarizing the period's financial results.
Healius Earnings Call Transcript: H1 2026
Revenue grew 3.8% to AUD 688.1 million in H1 FY26, with underlying EBITDA up 13.1% and EBIT improving to AUD 7.9 million. Cost savings, digital transformation, and high-value segment growth are driving margin expansion, with FY26 EBIT expected in line with consensus at around AUD 48 million.
Healius Quarterly report: H1 2026
Healius has published its H1 2026 quarterly earnings report on February 17, 2026.
Healius Slides: H1 2026
Healius has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 17, 2026.
Healius Earnings release: H1 2026
Healius released its H1 2026 earnings on February 17, 2026, summarizing the period's financial results.
Healius Transcript: AGM 2025
The AGM highlighted a successful year with the sale of Lumus Imaging, debt repayment, and a special dividend. Strategic focus remains on digital modernization, operational efficiency, and achieving high single-digit EBIT margins by FY 2027. Shareholders supported all resolutions, and the Board addressed concerns on cash flow, competition, and remuneration alignment.
Healius Earnings Call Transcript: H2 2025
Revenue grew 5.7% to AUD 1.34 billion, with pathology up 6% and genomics up 34.7%. Labor costs are targeted to remain flat in FY 2026, with AUD 15–20 million in cost savings planned. High single-digit margins are targeted by June 2027.
Healius Annual report: H2 2025
Healius has published its H2 2025 annual report on August 20, 2025.
Healius Annual report: H2 2025
Healius has published its H2 2025 annual report on August 20, 2025.
Healius Slides: H2 2025
Healius has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 20, 2025.
Healius Earnings release: H2 2025
Healius released its H2 2025 earnings on August 20, 2025, summarizing the period's financial results.